Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Tetanus toxin heavy chain C-terminal domain (TeNT-Hc), also known as Fragment C, is a 50 kDa protein domain derived from the tetanus neurotoxin produced by Clostridium tetani (UniProt P04958). It serves as the primary receptor-binding component, facilitating the toxin's attachment to the presynaptic membrane of motor neurons through a dual-receptor mechanism involving polysialogangliosides (GD1b, GT1b) and protein receptors such as nidogen-1 and nidogen-2 (Bercsenyi et al., 2014). Following binding, TeNT-Hc mediates the internalization and retrograde axonal transport of the toxin to the spinal cord, a process critical for the pathogenesis of tetanus (Lalli et al., 2003). In clinical practice, this domain is the target of neutralizing antibodies induced by the tetanus toxoid vaccine and those provided by tetanus immune globulin (StatPearls, 2023). Beyond its role in disease, TeNT-Hc is extensively utilized in biomedical research as a non-toxic molecular vehicle for delivering therapeutic agents, such as enzymes or genetic material, directly into the central nervous system (Rossetto et al., 2014). Its high affinity for neurons and ability to bypass the blood-brain barrier via retrograde transport make it a significant tool for treating neurodegenerative conditions in experimental models.
Neutralization of the binding domain to prevent neuronal entry and retrograde transport.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetanus toxin heavy chain C-terminal domain (TeNT-Hc) (TeNT-Hc).